Tags

Type your tag names separated by a space and hit enter

Lixisenatide versus insulin glulisine on top of insulin glargine in patients with type 2 diabetes mellitus: a cost-per-responder analysis in China.
Curr Med Res Opin. 2020 02; 36(2):213-217.CM

Abstract

Objective:

To compare the cost per responder of lixisenatide versus insulin glulisine once daily (basal-plus) and three times daily (basal-bolus) on top of basal insulin for the treatment of patients with type 2 diabetes mellitus (T2DM) inadequately controlled by basal insulin in China.

Methods:

The cost per responder was estimated based on clinical data obtained from the GetGoal Duo-2 clinical trial and direct medical costs from the perspective of the Chinese healthcare system over a 52-week time horizon. The response was assessed at week 26 in the clinical trial, which was extrapolated to 52 weeks to estimate the annual cost per responder. Responders were primarily defined using a composite endpoint that based on an HbA1c ≤ 7.0% threshold AND no weight gain With or Without no documented symptomatic hypoglycemia. Composite endpoints with varied HbA1c thresholds were defined in secondary analyses.

Results:

For the composite endpoint of HbA1c threshold ≤7.0% AND no weight gain, the annual cost per responder results were 96,722 CNY, 122,552 CNY and 135,926 CNY (14,616, 18,520 and 20,541 US dollars) for lixisenatide combined with basal insulin, basal-plus, and basal-bolus, respectively. For the composite endpoint of HbA1c threshold ≤7.0% AND no weight gain AND no documented symptomatic hypoglycemia, the annual cost per responder results were 136,290 CNY, 231,487 CNY and 222,424 CNY (20,596, 34,982 and 33,612 US dollars) for lixisenatide combined with basal insulin, basal-plus, and basal-bolus, respectively. The secondary analyses proved similar results.

Conclusion:

Lixisenatide combined with basal insulin is associated with a lower cost per responder compared with basal-plus and basal-bolus for T2DM patients inadequately controlled by basal insulin in China.

Authors+Show Affiliations

Department of Pharmacy, Peking University Third Hospital, Beijing, China. Institute for Drug Evaluation, Peking University Health Science Center, Beijing, China.Health Economics and Outcome Research, Sanofi, Shanghai, China.Department of Pharmacy, Peking University Third Hospital, Beijing, China. Institute for Drug Evaluation, Peking University Health Science Center, Beijing, China.Real World Insights, IQVIA, Shanghai, China.

Pub Type(s)

Journal Article
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

31469303

Citation

Men, Peng, et al. "Lixisenatide Versus Insulin Glulisine On Top of Insulin Glargine in Patients With Type 2 Diabetes Mellitus: a Cost-per-responder Analysis in China." Current Medical Research and Opinion, vol. 36, no. 2, 2020, pp. 213-217.
Men P, Li C, Zhai S, et al. Lixisenatide versus insulin glulisine on top of insulin glargine in patients with type 2 diabetes mellitus: a cost-per-responder analysis in China. Curr Med Res Opin. 2020;36(2):213-217.
Men, P., Li, C., Zhai, S., & Qu, S. (2020). Lixisenatide versus insulin glulisine on top of insulin glargine in patients with type 2 diabetes mellitus: a cost-per-responder analysis in China. Current Medical Research and Opinion, 36(2), 213-217. https://doi.org/10.1080/03007995.2019.1662676
Men P, et al. Lixisenatide Versus Insulin Glulisine On Top of Insulin Glargine in Patients With Type 2 Diabetes Mellitus: a Cost-per-responder Analysis in China. Curr Med Res Opin. 2020;36(2):213-217. PubMed PMID: 31469303.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Lixisenatide versus insulin glulisine on top of insulin glargine in patients with type 2 diabetes mellitus: a cost-per-responder analysis in China. AU - Men,Peng, AU - Li,Chaoyun, AU - Zhai,Suodi, AU - Qu,Shuli, Y1 - 2019/09/11/ PY - 2019/8/31/pubmed PY - 2019/8/31/medline PY - 2019/8/31/entrez KW - Lixisenatide KW - cost per responder KW - insulin glulisine QD KW - insulin glulisine TID KW - type 2 diabetes mellitus SP - 213 EP - 217 JF - Current medical research and opinion JO - Curr Med Res Opin VL - 36 IS - 2 N2 - Objective: To compare the cost per responder of lixisenatide versus insulin glulisine once daily (basal-plus) and three times daily (basal-bolus) on top of basal insulin for the treatment of patients with type 2 diabetes mellitus (T2DM) inadequately controlled by basal insulin in China.Methods: The cost per responder was estimated based on clinical data obtained from the GetGoal Duo-2 clinical trial and direct medical costs from the perspective of the Chinese healthcare system over a 52-week time horizon. The response was assessed at week 26 in the clinical trial, which was extrapolated to 52 weeks to estimate the annual cost per responder. Responders were primarily defined using a composite endpoint that based on an HbA1c ≤ 7.0% threshold AND no weight gain With or Without no documented symptomatic hypoglycemia. Composite endpoints with varied HbA1c thresholds were defined in secondary analyses.Results: For the composite endpoint of HbA1c threshold ≤7.0% AND no weight gain, the annual cost per responder results were 96,722 CNY, 122,552 CNY and 135,926 CNY (14,616, 18,520 and 20,541 US dollars) for lixisenatide combined with basal insulin, basal-plus, and basal-bolus, respectively. For the composite endpoint of HbA1c threshold ≤7.0% AND no weight gain AND no documented symptomatic hypoglycemia, the annual cost per responder results were 136,290 CNY, 231,487 CNY and 222,424 CNY (20,596, 34,982 and 33,612 US dollars) for lixisenatide combined with basal insulin, basal-plus, and basal-bolus, respectively. The secondary analyses proved similar results.Conclusion: Lixisenatide combined with basal insulin is associated with a lower cost per responder compared with basal-plus and basal-bolus for T2DM patients inadequately controlled by basal insulin in China. SN - 1473-4877 UR - https://www.unboundmedicine.com/medline/citation/31469303/Lixisenatide_versus_insulin_glulisine_on_top_of_insulin_glargine_in_patients_with_type_2_diabetes_mellitus:_a_cost_per_responder_analysis_in_China_ L2 - http://www.tandfonline.com/doi/full/10.1080/03007995.2019.1662676 DB - PRIME DP - Unbound Medicine ER -
Try the Free App:
Prime PubMed app for iOS iPhone iPad
Prime PubMed app for Android
Prime PubMed is provided
free to individuals by:
Unbound Medicine.